Biochemist Jennifer Doudna, a faculty scientist at the Department of Energy’s Lawrence Berkeley ... Doudna, who is also a Howard Hughes Medical Institute investigator, was honored for her work ...

Drs Emmanuelle Charpentier and Jennifer Doudna have won this year’s Nobel Prize for chemistry in recognition of their work on the gene-editing technology CRISPR/Cas9. Charpentier – currently ...

Jennifer Doudna, a UC Berkeley biochemist who shared the 2020 Nobel Prize in Chemistry for the invention of CRISPR-Cas9 genome editing, has been awarded a National Medal of Technology and Innovation, ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Several companies are also stepping away from the cas9 protein to develop their CRISPR-based therapies. Locus Biosciences is an example, with its CRISPR Cas3 anti-bacterial therapy technology. The ...

Scribe – which counts new Nobel Prize for chemistry winner Jennifer Doudna among its founders ... It will also use a variation of CRISPR/Cas9 known as CRISPR/Casx which is smaller, making ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

For example, the FDA-approved CRISPR-Cas9-based therapy Casgevy, designed to treat sickle cell disease, provides life-changing potential but comes at a staggering one-time cost of $2.2 million.

It feels fantastic,” said Blau, who thanked her lab members and colleagues for their support and dedication. “This achievement is a reflection of our collective efforts and ...

CRISPR-Cas9 technology – which allows scientists to precisely cut and modify DNA at specific locations within a genome – was discovered by Jennifer Doudna and Emmanuelle Charpentier in 2012.

Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation CRISPR gene editing platform to create potential one-time curative therapies, today announced new ...